Skip to content

Sotatercept improved walking performance in adults with pulmonary arterial hypertension

Adults with high blood pressure in the lung arteries walked farther with sotatercept than placebo in pooled trials. Low platelet counts were more frequent, and follow-up duration was unspecified.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Sotatercept improved walking-test performance compared with placebo in adults with pulmonary arterial hypertension. The review also reported fewer deaths and cases of right ventricular failure, meaning failure of the heart's right pumping chamber. These findings came alongside an increased risk of low platelet counts; the abstract does not report follow-up duration.

Keep in mind

The abstract omits follow-up durations and absolute event counts for deaths and adverse effects. Those omissions limit assessment of how often benefits and harms occurred and whether differences persisted over time.

THE RESULT, WITH CONTEXT

What researchers found

Participants walked farther during the timed test.

Six-minute walk distance

Sotatercept versus placebo: pooled mean difference 40.17 m (95% confidence interval 15.14–65.19). Treatment follow-up duration was not reported in the abstract.

Naunyn Schmiedebergs Arch Pharmacol, 2025 · Original source ↓

Different kinds of outcomes

The review assessed walking performance, functional status, blood measurements and circulation measurements alongside deaths and heart failure. Improvements in a blood marker are separate evidence from changes in clinical events, even when both favor treatment.

The safety tradeoff

Thrombocytopenia means a low platelet count. This outcome was more frequent with sotatercept than placebo. The abstract supplies a relative risk estimate, but no absolute counts that would show how common the problem was.

CHECK THE ORIGINAL

The original publication

Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.

Shalabi L, Tabassum S, Al Zoubi BM et al.
Naunyn Schmiedebergs Arch Pharmacol · 2025

PubMed ID
40668414
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.